About IBA
IBA is a publicly listed company based in Louvain-la-neuve (Belgium) founded in 1986 by Yves Jongen. Innovative solutions for cancer treatment and industrial applications are provided by IBA. It operates on a Professional Services and Direct-to-Consumer (D2C) model. IBA has raised $27.32 million across 11 funding rounds from investors including European Union, SRIW and SFPIM. The company has 26 employees. IBA has completed 3 acquisitions, including Modus QA, PhantomX and Radcal. Its website iba-worldwide.com draws about 40 thousand monthly visits. Its Indian entity Curium Pharma (India) Private Limited reported revenue of ₹41.38 Cr. IBA offers products and services including Proton Therapy, Dosimetry Solutions, RadioPharma Solutions, and Industrial Solutions. Its focus areas include Medical Devices, Radiation Therapy Equipment, Technology and Industrial Technology.
Company details
Solutions for cancer diagnosis and treatment are designed and marketed by IBA, focusing on proton therapy and dosimetry. Industrial applications such as medical device sterilization are also addressed. Sectors including healthcare and industrial technology are served with advanced equipment and services. Integrated radiopharma solutions and cyclotrons are developed for medical imaging and diagnostics. Sustainability and scientific innovation are emphasized through the IBA Discovery Lab.
- Headquarters Louvain-la-neuve, Belgium
- Employees 26
- Founders Yves Jongen
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website iba-worldwide.com
- Social LinkedIn X Facebook Instagram
- Legal Name Iba Worldwide
- Date of Incorporation 24 Dec, 2004
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹41.38 Cr
FY 2025 · -3% YoY
- Indian entity net profit₹4.53 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹7.31 Cr
FY 2025 · 18% margin
- Total Equity Funding$27.32M (USD)
in 11 rounds
- Latest Funding Round$260.73K (USD), Grant
Nov 2021
- InvestorsEuropean Union
& 2 more
- Employee Count26
- Investments & AcquisitionsModus QA
& 2 more
Associated legal entities of IBA
IBA operates through Curium Pharma (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Curium Pharma (India) Private Limited CIN U24230MH2004PTC150212 | Active | 24 Dec 2004 | Mumbai, Maharashtra | ₹41.4 Cr | 26 | 4 | View details |
Products & Services of IBA
IBA offers a comprehensive portfolio of products and services, including Proton Therapy, Dosimetry Solutions, RadioPharma Solutions, and Industrial Solutions.
Advanced cancer treatment using proton beam technology is provided.
Quality assurance tools for radiation therapy are offered.
Radiochemistry and cyclotron solutions for diagnostics are developed.
Sterilization solutions for medical devices are engineered.
Funding Insights of IBA
IBA has successfully raised a total of $27.32M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $260.73 thousand completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $27.32M
- Total Rounds 11
- Last Round Grant — $260,729
- First Round $27.32M
(Jun 2014)
- Investors Count 3
Latest 10 of 11 funding rounds of IBA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $260,729 | Grant | – | – | |
| Aug 2020 | $195,885 | Grant | – | – | |
| Jun 2018 | $1.66M | Grant | – | – | |
| Mar 2018 | Grant | – | – | ||
| Jan 2018 | $1.72M | Grant | – | – | |
| Jan 2018 | Grant | – | – | ||
| May 2017 | $92,720 | Grant | – | – | |
| Mar 2016 | $315,451 | Grant | – | – | |
| Feb 2016 | $272,998 | Grant | – | – | |
| Apr 2015 | $651,152 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in IBA
IBA has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, SRIW and SFPIM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Buyouts are pursued by SRIW as a private equity firm. | sriw.be | Liege, Belgium | ||
Private equity is directed toward private and public companies. | sfpi-fpim.be | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for IBA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Curium Pharma (India) Private Limited (IBA)
Curium Pharma (India) Private Limited is the primary company behind IBA. The board of Curium Pharma (India) Private Limited currently have 3 directors; the longest-serving is Xavier Anne J Defourt, appointed in 2020. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Xavier Anne J Defourt DIN 08950913 | Director | 11 Nov 2020 | 5 yrs 11 mo | Curium Pharma (India) Private Limited |
| Susamoy Mishra DIN 10523783 | Director | 26 Feb 2024 | 2 yrs 8 mo | Curium Pharma (India) Private Limited |
| Mustafa Aydin Kucuk DIN 11585722 | Additional Director | 10 Mar 2026 | 8 mo | Curium Pharma (India) Private Limited |
People of IBA
243 people are tracked at IBA (38 in leadership, 6 in board & advisors, 199 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Yves Jongen | Founder & Chief Research Officer | Leadership |
Frédéric Nolf | Chief Human Resources & Sustainability Officer | Leadership |
Francoise Vamecq | Director Philanthropic Alliances | Leadership |
Yves Claereboudt | R&d Director - Product Engineering, Control & Platforms | Leadership |
Marc Modave | RD PT - Head Of Engineering | Leadership |
Sabina Puppo | Head Of People, Americas | Leadership |
Henri de Romrée | Chief Strategy Officer (cso) | Leadership |
Jean-Marc Bothy | Chief Strategy Officer | Leadership |
Charles Kumps | Chief Innovation And Development Officer | Leadership |
Dr. Ronald Wichern | Chief Quality Officer | Leadership |
Inez Wathion | Head Of Proton Therapy Release, Complaints & Vigilance | Leadership |
Luk Herremans | Chief Market Officer | Leadership |
Mary Elizabeth Klein | President, IBA Proton Therapy North America | Leadership |
Ali Onuralp | Vice President Commercial Operations Americas | Leadership |
Christian Matton | Chief Legal Officer | Leadership |
Evelyne Loriaux | Head Of Sales Administration | Leadership |
Julie Rassart | Service Strategy Director | Leadership |
Steven Ko | Head Of Sales, Asia Region | Leadership |
Sylvain Savaria | Vice President Sales | Leadership |
Olivier Legrain | CEO | Leadership |
223 more people are available in the full profile.
Complete people profiles for IBA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of IBA
Figures of Curium Pharma (India) Private Limited, the primary company behind IBA, for FY 2025. Revenue was ₹41.38 Cr (-3% year on year). Net profit was ₹4.53 Cr (11% margin). EBITDA was ₹7.31 Cr (18% margin). Revenue has grown at a compounded annual rate of +9% over three years and +12% over five years.
- ₹41.38 CrRevenue · FY 2025 · -3% YoY
- ₹4.53 CrNet profit · 11% margin
- ₹7.31 CrEBITDA · 18% margin
- ₹10.30 CrPaid-up capital
- 26Employees (provident fund records)
- +9%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Curium Pharma (India) Private Limited are on its company page.
Detailed financial statements for IBA
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IBA
IBA has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Modus QA, PhantomX and Radcal.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provides realistic phantoms for medical imaging, AI training, and diagnostic testing. | phantomx.de | Germany | 2021 | Nov 2025 | •••• | |
Diagnostic X-ray imaging solutions are provided for medical practitioners. | radcal.com | Monrovia, United States | 1980 | Feb 2024 | •••• | |
Advanced radiotherapy and medical imaging devices are manufactured. | modusqa.com | London, Canada | 2000 | May 2022 | •••• |
Complete acquisition details for IBA
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of IBA
7 dated milestones of IBA across 39 years, from founding to its latest funding, stage changes and deals.
Web traffic of IBA
The website of IBA (iba-worldwide.com) receives about 40.4K visits a month.
- Monthly visits40.4K
▲ 6.5% vs previous month
Websites whose visitors overlap most with IBA. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
iba-dosimetry.com | iba-dosimetry.com | 100% | #588,564 | – | |
| iba-radiopharmasolutions.com | 83% | #3,532,970 | View details | ||
healthcarebelgium.com | healthcarebelgium.com | 72% | – | ||
| accuray.com | 56% | 22K | #1,313,331 | View details | |
ibatpa.com | ibatpa.com | 54% | #1,854,623 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for IBA
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iba
Complete news archive for IBA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IBA
IBA was founded in 1986 and raised its 1st funding round 28 years after it was founded.
IBA is headquartered in Louvain-la-neuve, Belgium.
IBA is a funded company, having raised a total of $27.32M across 11 funding rounds to date. The company's 1st funding round was a Grant of $651.15K, raised on Jun 2014.
IBA has 26 employees.
The primary company behind IBA, Curium Pharma (India) Private Limited, reported revenue of ₹41.38 Cr for FY 2025, down 3% year on year.
Solutions for cancer diagnosis and treatment are designed and marketed by IBA, focusing on proton therapy and dosimetry. Industrial applications such as medical device sterilization are also addressed. Sectors including healthcare and industrial technology are served with advanced equipment and services. Integrated radiopharma solutions and cyclotrons are developed for medical imaging and diagnostics. Sustainability and scientific innovation are emphasized through the IBA Discovery Lab.
IBA offers Proton Therapy, Dosimetry Solutions, RadioPharma Solutions, and Industrial Solutions.
IBA has 3 investors. Key investors include European Union, SRIW, and SFPIM.
IBA operates through Curium Pharma (India) Private Limited.
The legal entities of IBA currently have 4 directors, including Xavier Anne J Defourt, Shikha Gupta, Mustafa Aydin Kucuk and others.